Urogenital Neoplasms clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
Sacramento, California and other locations
Our lead scientists for Urogenital Neoplasms research studies include Tianhong Li, MD.
Last updated: